Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
Viral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be v...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4667969?pdf=render |
id |
doaj-e27f0af4b9674333b40c80b2912e51a7 |
---|---|
record_format |
Article |
spelling |
doaj-e27f0af4b9674333b40c80b2912e51a72020-11-25T02:31:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014363110.1371/journal.pone.0143631Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.Scott M BerryHannah M PezziEram D WilliamsJennifer M LoebDavid J GuckenbergerAlex J LavanwayAlice A PuchalskiCissy M KityoPeter N MugyenyiFranklin M GrazianoDavid J BeebeViral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be validated on metrics of limit of detection (LOD), accuracy, and dynamic range. Patient plasma samples from the Joint Clinical Research Centre in Uganda were de-identified and measured using both an existing VL assay (Abbott RealTime HIV-1) and our assay, which combines low cost reagents with a simplified method of RNA isolation termed Exclusion-Based Sample Preparation (ESP).71 patient samples with VLs ranging from <40 to >3,000,000 copies/mL were used to compare the two methods. We demonstrated equivalent LOD (~50 copies/mL) and high accuracy (average difference between methods of 0.08 log, R2 = 0.97). Using expenditures from this trial, we estimate that the cost of the reagents and consumables for this assay to be approximately $5 USD. As cost is a significant barrier to implementation of VL testing, we anticipate that our assay will enhance access to this critical monitoring test in developing countries.http://europepmc.org/articles/PMC4667969?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Scott M Berry Hannah M Pezzi Eram D Williams Jennifer M Loeb David J Guckenberger Alex J Lavanway Alice A Puchalski Cissy M Kityo Peter N Mugyenyi Franklin M Graziano David J Beebe |
spellingShingle |
Scott M Berry Hannah M Pezzi Eram D Williams Jennifer M Loeb David J Guckenberger Alex J Lavanway Alice A Puchalski Cissy M Kityo Peter N Mugyenyi Franklin M Graziano David J Beebe Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. PLoS ONE |
author_facet |
Scott M Berry Hannah M Pezzi Eram D Williams Jennifer M Loeb David J Guckenberger Alex J Lavanway Alice A Puchalski Cissy M Kityo Peter N Mugyenyi Franklin M Graziano David J Beebe |
author_sort |
Scott M Berry |
title |
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. |
title_short |
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. |
title_full |
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. |
title_fullStr |
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. |
title_full_unstemmed |
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. |
title_sort |
using exclusion-based sample preparation (esp) to reduce viral load assay cost. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Viral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be validated on metrics of limit of detection (LOD), accuracy, and dynamic range. Patient plasma samples from the Joint Clinical Research Centre in Uganda were de-identified and measured using both an existing VL assay (Abbott RealTime HIV-1) and our assay, which combines low cost reagents with a simplified method of RNA isolation termed Exclusion-Based Sample Preparation (ESP).71 patient samples with VLs ranging from <40 to >3,000,000 copies/mL were used to compare the two methods. We demonstrated equivalent LOD (~50 copies/mL) and high accuracy (average difference between methods of 0.08 log, R2 = 0.97). Using expenditures from this trial, we estimate that the cost of the reagents and consumables for this assay to be approximately $5 USD. As cost is a significant barrier to implementation of VL testing, we anticipate that our assay will enhance access to this critical monitoring test in developing countries. |
url |
http://europepmc.org/articles/PMC4667969?pdf=render |
work_keys_str_mv |
AT scottmberry usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT hannahmpezzi usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT eramdwilliams usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT jennifermloeb usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT davidjguckenberger usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT alexjlavanway usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT aliceapuchalski usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT cissymkityo usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT peternmugyenyi usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT franklinmgraziano usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost AT davidjbeebe usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost |
_version_ |
1724824881168646144 |